The Center for Advanced Genetic Screens

Cellecta is a contract research organization whose primary focus is to develop advanced high-throughput (HT) genetic screen technologies and their applications for the discovery and functional characterization of novel therapeutic targets and drugs.

With more than 7 years of experience performing HT genetic screens, Cellecta is at the forefront of the HT genetic screening revolution.

> Learn more about our products and services
> Learn more about Cellecta

HT Sequencing Results

High-Throughput RNAi Screens with Pooled shRNA Libraries

Next generation, cost-effective RNAi screens with pooled bar-coded lentiviral shRNA libraries compatible with HT sequencing. Choose any or all steps, from library construction to screening to data analysis.

Cellecta, partnered with Agilent and Illumina, has created the most advanced, most powerful pooled shRNA library platform available anywhere.

 

Bioactive Peptide Screen diagram

High-Throughput Screening for Bioactive Peptides

Cellecta introduces a novel proprietary technological platform for cost-effective HTS of 50K-500K rationally designed peptides for biological activity in a wide range of disease-relevant cell models. Search the new "druggable" space to develop next-generation biologics with unique mechanisms of action against drug targets.

 

293T cells expressing RFP

Stable Reporter and Overexpression Cell Line Development

Using lentiviral technology, we can generate customized transcriptional reporter, overexpression, and knockdown stable cell lines using GFP, RFP, PuroR, or other marker.

 

Brochure

BrochureView the company brochure for an overview of Cellecta's HT Genetic Screen services.

> Download Now

Upcoming Events

April 7-9, 2010
The 2010 Illumina User Symposium, Napa, CA (presentation)

Cellecta President & CEO Alex Chenchik will speak on "RNAi Genetic Screens Utilizing Bar-Code HT Sequencing."

April 17-22, 2010
AACR 2010, Washington, D.C. (exhibit booth #911)

Visit Cellecta at booth 911 at the 2010 AACR Annual Meeting in Washington, D.C. to learn about the latest HT RNAi and bioactive peptide library screening technologies and services.